SG11201906880VA - Engineered phenylalanine ammonia lyase polypeptides - Google Patents
Engineered phenylalanine ammonia lyase polypeptidesInfo
- Publication number
- SG11201906880VA SG11201906880VA SG11201906880VA SG11201906880VA SG11201906880VA SG 11201906880V A SG11201906880V A SG 11201906880VA SG 11201906880V A SG11201906880V A SG 11201906880VA SG 11201906880V A SG11201906880V A SG 11201906880VA SG 11201906880V A SG11201906880V A SG 11201906880VA
- Authority
- SG
- Singapore
- Prior art keywords
- pal
- california
- polypeptides
- fessif
- redwood city
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/88—Lyases (4.)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y403/00—Carbon-nitrogen lyases (4.3)
- C12Y403/01—Ammonia-lyases (4.3.1)
- C12Y403/01024—Phenylalanine ammonia-lyase (4.3.1.24)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Dermatology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762458232P | 2017-02-13 | 2017-02-13 | |
US201762565555P | 2017-09-29 | 2017-09-29 | |
PCT/US2018/017773 WO2018148633A1 (en) | 2017-02-13 | 2018-02-12 | Engineered phenylalanine ammonia lyase polypeptides |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201906880VA true SG11201906880VA (en) | 2019-08-27 |
Family
ID=63106144
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201906880VA SG11201906880VA (en) | 2017-02-13 | 2018-02-12 | Engineered phenylalanine ammonia lyase polypeptides |
Country Status (15)
Country | Link |
---|---|
US (4) | US10995329B2 (ko) |
EP (1) | EP3579867A4 (ko) |
JP (2) | JP2020505942A (ko) |
KR (1) | KR102573324B1 (ko) |
CN (1) | CN110573175A (ko) |
AU (1) | AU2018217495B2 (ko) |
BR (1) | BR112019016634A2 (ko) |
CA (1) | CA3051262A1 (ko) |
IL (1) | IL268226A (ko) |
MX (1) | MX2019009615A (ko) |
MY (1) | MY196740A (ko) |
NZ (1) | NZ755628A (ko) |
PH (1) | PH12019501705A1 (ko) |
SG (1) | SG11201906880VA (ko) |
WO (1) | WO2018148633A1 (ko) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3102968A1 (en) | 2018-06-12 | 2019-12-19 | Codexis, Inc. | Engineered tyrosine ammonia lyase |
CN112355034B (zh) | 2020-11-17 | 2021-08-06 | 同济大学 | 基于水热钙离子调配的有机固体废弃物无害化预处理方法 |
CN115518691B (zh) * | 2022-10-14 | 2023-11-21 | 天津大学 | 一种具有类漆酶活性的人工酶及制备方法和应用 |
Family Cites Families (76)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK75593D0 (ko) * | 1993-06-25 | 1993-06-25 | Novo Nordisk As | |
US20060257890A1 (en) | 1996-05-20 | 2006-11-16 | Maxygen, Inc. | Methods and compositions for cellular and metabolic engineering |
US6995017B1 (en) | 1994-02-17 | 2006-02-07 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
US6406855B1 (en) | 1994-02-17 | 2002-06-18 | Maxygen, Inc. | Methods and compositions for polypeptide engineering |
US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
US5834252A (en) | 1995-04-18 | 1998-11-10 | Glaxo Group Limited | End-complementary polymerase reaction |
US6165793A (en) | 1996-03-25 | 2000-12-26 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
US6117679A (en) | 1994-02-17 | 2000-09-12 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
US6335160B1 (en) | 1995-02-17 | 2002-01-01 | Maxygen, Inc. | Methods and compositions for polypeptide engineering |
US5837458A (en) | 1994-02-17 | 1998-11-17 | Maxygen, Inc. | Methods and compositions for cellular and metabolic engineering |
US6395547B1 (en) | 1994-02-17 | 2002-05-28 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
US6309883B1 (en) | 1994-02-17 | 2001-10-30 | Maxygen, Inc. | Methods and compositions for cellular and metabolic engineering |
US5928905A (en) | 1995-04-18 | 1999-07-27 | Glaxo Group Limited | End-complementary polymerase reaction |
AU694954B2 (en) | 1994-06-03 | 1998-08-06 | Novo Nordisk A/S | Purified myceliophthora laccases and nucleic acids encoding same |
WO1996000787A1 (en) | 1994-06-30 | 1996-01-11 | Novo Nordisk Biotech, Inc. | Non-toxic, non-toxigenic, non-pathogenic fusarium expression system and promoters and terminators for use therein |
FI104465B (fi) | 1995-06-14 | 2000-02-15 | Valio Oy | Proteiinihydrolysaatteja allergioiden hoitamiseksi tai estämiseksi, niiden valmistus ja käyttö |
US6096548A (en) | 1996-03-25 | 2000-08-01 | Maxygen, Inc. | Method for directing evolution of a virus |
US6506602B1 (en) | 1996-03-25 | 2003-01-14 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
AU743305C (en) | 1997-01-17 | 2006-03-30 | Maxygen, Inc. | Evolution of whole cells and organisms by recursive sequence recombination |
US7148054B2 (en) | 1997-01-17 | 2006-12-12 | Maxygen, Inc. | Evolution of whole cells and organisms by recursive sequence recombination |
US6326204B1 (en) | 1997-01-17 | 2001-12-04 | Maxygen, Inc. | Evolution of whole cells and organisms by recursive sequence recombination |
WO1998031816A1 (en) | 1997-01-17 | 1998-07-23 | Regents Of The University Of Minnesota | Dna molecules and protein displaying improved triazine compound degrading ability |
JP3712255B2 (ja) | 1997-12-08 | 2005-11-02 | カリフォルニア・インスティチュート・オブ・テクノロジー | ポリヌクレオチドおよびポリペプチド配列を生成するための方法 |
JP2002510506A (ja) | 1998-04-02 | 2002-04-09 | テラス ジェネティック リソーシズ,インコーポレイティド | 遺伝子配列に遺伝障害を有する植物を得る方法 |
AU747190B2 (en) | 1998-05-01 | 2002-05-09 | Maxygen, Inc. | "Optimization of pest resistance genes using DNA shuffling" |
JP2002517995A (ja) | 1998-06-17 | 2002-06-25 | マキシジェン, インコーポレイテッド | 所望の特性を有するポリヌクレオチドを生成するための方法 |
US6365408B1 (en) | 1998-06-19 | 2002-04-02 | Maxygen, Inc. | Methods of evolving a polynucleotides by mutagenesis and recombination |
AU5347999A (en) | 1998-08-12 | 2000-03-06 | Maxygen, Inc. | Dna shuffling of monooxygenase genes for production of industrial chemicals |
CA2345203A1 (en) | 1998-10-07 | 2000-04-13 | Maxygen Inc. | Dna shuffling to produce nucleic acids for mycotoxin detoxification |
EP1129184A1 (en) | 1998-11-10 | 2001-09-05 | Maxygen, Inc. | Modified adp-glucose pyrophosphorylase for improvement and optimation of plant phenotypes |
JP4221100B2 (ja) | 1999-01-13 | 2009-02-12 | エルピーダメモリ株式会社 | 半導体装置 |
US6917882B2 (en) | 1999-01-19 | 2005-07-12 | Maxygen, Inc. | Methods for making character strings, polynucleotides and polypeptides having desired characteristics |
US6376246B1 (en) | 1999-02-05 | 2002-04-23 | Maxygen, Inc. | Oligonucleotide mediated nucleic acid recombination |
US6436675B1 (en) | 1999-09-28 | 2002-08-20 | Maxygen, Inc. | Use of codon-varied oligonucleotide synthesis for synthetic shuffling |
US6368861B1 (en) | 1999-01-19 | 2002-04-09 | Maxygen, Inc. | Oligonucleotide mediated nucleic acid recombination |
ES2341217T3 (es) | 1999-01-19 | 2010-06-17 | Maxygen, Inc. | Recombinacion de acidos nucleicos mediada por oligonucleotidos. |
US6961664B2 (en) | 1999-01-19 | 2005-11-01 | Maxygen | Methods of populating data structures for use in evolutionary simulations |
US8457903B1 (en) | 1999-01-19 | 2013-06-04 | Codexis Mayflower Holdings, Llc | Method and/or apparatus for determining codons |
US20070065838A1 (en) | 1999-01-19 | 2007-03-22 | Maxygen, Inc. | Oligonucleotide mediated nucleic acid recombination |
US7873477B1 (en) | 2001-08-21 | 2011-01-18 | Codexis Mayflower Holdings, Llc | Method and system using systematically varied data libraries |
US7024312B1 (en) | 1999-01-19 | 2006-04-04 | Maxygen, Inc. | Methods for making character strings, polynucleotides and polypeptides having desired characteristics |
US7702464B1 (en) | 2001-08-21 | 2010-04-20 | Maxygen, Inc. | Method and apparatus for codon determining |
IL144657A0 (en) | 1999-02-11 | 2002-06-30 | Maxygen Inc | High throughput mass spectrometry |
US6365377B1 (en) | 1999-03-05 | 2002-04-02 | Maxygen, Inc. | Recombination of insertion modified nucleic acids |
US6703240B1 (en) | 1999-04-13 | 2004-03-09 | Maxygar, Inc. | Modified starch metabolism enzymes and encoding genes for improvement and optimization of plant phenotypes |
US7430477B2 (en) | 1999-10-12 | 2008-09-30 | Maxygen, Inc. | Methods of populating data structures for use in evolutionary simulations |
US6519065B1 (en) | 1999-11-05 | 2003-02-11 | Jds Fitel Inc. | Chromatic dispersion compensation device |
US6686515B1 (en) | 1999-11-23 | 2004-02-03 | Maxygen, Inc. | Homologous recombination in plants |
IL150291A0 (en) | 2000-01-11 | 2002-12-01 | Maxygen Inc | Integrated systems and methods for diversity generation and screening |
WO2001075767A2 (en) | 2000-03-30 | 2001-10-11 | Maxygen, Inc. | In silico cross-over site selection |
DE60144145D1 (de) | 2000-04-03 | 2011-04-14 | Maxygen Inc | Subtilisin-variante |
US7747391B2 (en) | 2002-03-01 | 2010-06-29 | Maxygen, Inc. | Methods, systems, and software for identifying functional biomolecules |
US20050084907A1 (en) | 2002-03-01 | 2005-04-21 | Maxygen, Inc. | Methods, systems, and software for identifying functional biomolecules |
EP2278509B1 (en) | 2002-03-01 | 2014-11-19 | Codexis Mayflower Holdings, LLC | Methods, systems, and software for identifying functional biomolecules |
US7620500B2 (en) | 2002-03-09 | 2009-11-17 | Maxygen, Inc. | Optimization of crossover points for directed evolution |
US8003356B2 (en) | 2004-04-20 | 2011-08-23 | E. I. Du Pont De Nemours And Company | Methods for the preparation of para-hydroxycinnamic acid and cinnamic acid at alkaline pH |
WO2006099207A2 (en) | 2005-03-10 | 2006-09-21 | Diversa Corporation | Lyase enzymes, nucleic acids encoding them and methods for making and using them |
US7531341B1 (en) | 2006-06-12 | 2009-05-12 | Biomarin Pharmaceutical Inc. | Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof |
US7534595B2 (en) | 2006-06-12 | 2009-05-19 | Biomarin Pharmaceutical Inc. | Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof |
US7537923B2 (en) | 2007-08-17 | 2009-05-26 | Biomarin Pharmaceutical Inc. | Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof |
EP2250594B1 (en) | 2008-02-12 | 2017-04-19 | Codexis, Inc. | Method of generating an optimized, diverse population of variants |
EP2250595B1 (en) | 2008-02-12 | 2017-06-14 | Codexis, Inc. | Method of selecting an optimized diverse population of variants |
US8383346B2 (en) | 2008-06-13 | 2013-02-26 | Codexis, Inc. | Combined automated parallel synthesis of polynucleotide variants |
CN102066561B (zh) | 2008-06-13 | 2013-09-25 | 科德克希思公司 | 合成多核苷酸变体的方法 |
US20090312196A1 (en) | 2008-06-13 | 2009-12-17 | Codexis, Inc. | Method of synthesizing polynucleotide variants |
WO2013003290A1 (en) | 2011-06-28 | 2013-01-03 | Codexis, Inc. | Protein variant generation by region shuffling |
HUE039516T2 (hu) | 2010-02-04 | 2019-01-28 | Biomarin Pharm Inc | Eljárás prokarióta fenilalanin-liáz variánsok tisztítására |
US20130340119A1 (en) | 2010-11-05 | 2013-12-19 | Basf Plant Science Company Gmbh | Method for Increasing Yield and Fine Chemical Production in Plants |
US9150884B2 (en) | 2011-03-08 | 2015-10-06 | Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University | Microbial conversion of glucose to styrene and its derivatives |
WO2012178126A1 (en) | 2011-06-23 | 2012-12-27 | Phytogene, Inc. | Enzymatic system for monomer synthesis |
US20150050658A1 (en) | 2012-03-15 | 2015-02-19 | Codexix, Inc. | Gene shuffling methods |
JP6377078B2 (ja) | 2013-01-31 | 2018-08-22 | コデクシス, インコーポレイテッド | 相互作用する構成要素を有する生体分子を同定するための方法、システム、およびソフトウェア |
WO2014172541A2 (en) * | 2013-04-18 | 2014-10-23 | Codexis, Inc. | Engineered phenylalanine ammonia lyase polypeptides |
EP3049973B1 (en) | 2013-09-27 | 2018-08-08 | Codexis, Inc. | Automated screening of enzyme variants |
EP3049979B1 (en) | 2013-09-27 | 2020-01-01 | Codexis, Inc. | Structure based predictive modeling |
JP6702866B2 (ja) * | 2013-11-18 | 2020-06-03 | ルビウス セラピューティクス, インコーポレイテッド | 合成膜−レシーバー複合体 |
-
2018
- 2018-02-12 EP EP18750620.9A patent/EP3579867A4/en active Pending
- 2018-02-12 AU AU2018217495A patent/AU2018217495B2/en active Active
- 2018-02-12 WO PCT/US2018/017773 patent/WO2018148633A1/en active Application Filing
- 2018-02-12 CA CA3051262A patent/CA3051262A1/en active Pending
- 2018-02-12 US US15/894,446 patent/US10995329B2/en active Active
- 2018-02-12 MX MX2019009615A patent/MX2019009615A/es unknown
- 2018-02-12 NZ NZ755628A patent/NZ755628A/en unknown
- 2018-02-12 KR KR1020197025645A patent/KR102573324B1/ko active IP Right Grant
- 2018-02-12 JP JP2019543213A patent/JP2020505942A/ja active Pending
- 2018-02-12 BR BR112019016634A patent/BR112019016634A2/pt unknown
- 2018-02-12 MY MYPI2019004314A patent/MY196740A/en unknown
- 2018-02-12 CN CN201880025923.9A patent/CN110573175A/zh active Pending
- 2018-02-12 SG SG11201906880VA patent/SG11201906880VA/en unknown
-
2019
- 2019-07-23 IL IL268226A patent/IL268226A/en unknown
- 2019-07-24 PH PH12019501705A patent/PH12019501705A1/en unknown
-
2021
- 2021-03-31 US US17/219,494 patent/US20210222145A1/en not_active Abandoned
-
2022
- 2022-05-17 JP JP2022080791A patent/JP2022103296A/ja active Pending
-
2023
- 2023-01-13 US US18/154,388 patent/US20230295598A1/en not_active Abandoned
- 2023-01-13 US US18/154,475 patent/US20230295599A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU2018217495B2 (en) | 2021-03-04 |
WO2018148633A1 (en) | 2018-08-16 |
EP3579867A4 (en) | 2021-03-10 |
MY196740A (en) | 2023-05-03 |
NZ755628A (en) | 2023-09-29 |
US20230295598A1 (en) | 2023-09-21 |
JP2022103296A (ja) | 2022-07-07 |
KR20190117577A (ko) | 2019-10-16 |
PH12019501705A1 (en) | 2020-07-06 |
US10995329B2 (en) | 2021-05-04 |
MX2019009615A (es) | 2019-10-14 |
CN110573175A (zh) | 2019-12-13 |
CA3051262A1 (en) | 2018-08-16 |
US20210222145A1 (en) | 2021-07-22 |
EP3579867A1 (en) | 2019-12-18 |
BR112019016634A2 (pt) | 2020-04-07 |
KR102573324B1 (ko) | 2023-08-30 |
IL268226A (en) | 2019-09-26 |
US20180230448A1 (en) | 2018-08-16 |
AU2018217495A1 (en) | 2019-08-08 |
US20230295599A1 (en) | 2023-09-21 |
JP2020505942A (ja) | 2020-02-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201906891RA (en) | Methods for the administration of certain vmat2 inhibitors | |
SG11201909957TA (en) | Engineered ligase variants | |
SG11201908391XA (en) | Methods for modulating an immune response | |
SG11201908719QA (en) | Biomarkers and car t cell therapies with enhanced efficacy | |
SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
SG11201805645QA (en) | Lsd1 inhibitors | |
SG11201808990QA (en) | Compositions for topical application of compounds | |
SG11201810983PA (en) | Novel heterocyclic derivatives useful as shp2 inhibitors | |
SG11201805422WA (en) | Multivalent and multispecific ox40-binding fusion proteins | |
SG11201803958WA (en) | Nucleic acids encoding repetitive amino acid sequences rich in proline and alanine residues that have low repetitive nucleotide sequences | |
SG11201909949XA (en) | Targeted immunotolerance | |
SG11201803920TA (en) | Compounds and compositions useful for treating disorders related to ntrk | |
SG11201900746RA (en) | Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions | |
SG11201811470PA (en) | Pyrazolopyrimidine derivatives as kinase inhibitor | |
SG11201908786VA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
SG11201810525XA (en) | Anti-gitr antibodies and uses thereof | |
SG11201408821SA (en) | Selective pi3k delta inhibitors | |
SG11201407579QA (en) | Interleukin-2 fusion proteins and uses thereof | |
SG11201908465QA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
SG11201901438VA (en) | Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate | |
SG11201807596YA (en) | Gitr antibodies, methods, and uses | |
SG11201906880VA (en) | Engineered phenylalanine ammonia lyase polypeptides | |
SG11201903012RA (en) | Anti-c1s antibodies and methods of use thereof | |
SG11201810965YA (en) | 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors | |
SG11201903348UA (en) | Therapeutic compounds and methods of use thereof |